pentetic acid has been researched along with Anemia, Sickle Cell in 2 studies
Pentetic Acid: An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium.
Anemia, Sickle Cell: A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Group A (n = 20) had sickle cell anemia without clinical evidence of cerebrovascular disease." | 1.29 | Cerebral perfusion in children: detection with dynamic contrast-enhanced T2*-weighted MR images. ( Ball, WS; Dunn, RS; Kirks, DR; Majumdar, S; Massoth, RJ; Tzika, AA, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ware, RE | 1 |
| Rees, RC | 1 |
| Sarnaik, SA | 1 |
| Iyer, RV | 1 |
| Alvarez, OA | 1 |
| Casella, JF | 1 |
| Shulkin, BL | 1 |
| Shalaby-Rana, E | 1 |
| Strife, CF | 1 |
| Miller, JH | 1 |
| Lane, PA | 1 |
| Wang, WC | 1 |
| Miller, ST | 1 |
| Tzika, AA | 1 |
| Massoth, RJ | 1 |
| Ball, WS | 1 |
| Majumdar, S | 1 |
| Dunn, RS | 1 |
| Kirks, DR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG)[NCT00006400] | Phase 3 | 193 participants (Actual) | Interventional | 2000-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
DTPA GFR was originally a co-primary efficacy outcome for the study. Later in May 29, 2009, this measurement was discontinued because of statistical futility (an extremely small chance that the difference between treatment groups would be statistically significant for this outcome) and the small risk posed by the radiation exposure involved with performing the DTPA GFR test. Subjects who had missing data at baseline or 2 years measurement were excluded from the analysis (29 subjects from the hydroxurea, and 31 subjects from the placebo group excluded). (NCT00006400)
Timeframe: Before initiation of treatment and at 2 years
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Hydroxyurea | 22.56 |
| Placebo | 20.74 |
GFR was calculated using new Schwartz formula: 39.1× [height (cm)/serum creatinine (mg/dL)]0.516 × [1.8/cystatin C]0.294 × [30/blood urea nitrogen]0.169 × [1.099]if male × [height(m)/1.4]0.188. Children with missing baseline or 2 years GFR were excluded from the analysis. (NCT00006400)
Timeframe: Before initiation of treatment and at 2 years
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Hydroxyurea | 10.57 |
| Placebo | 14.33 |
Schwartz formula used to calculate GFR is: 0.55× height (cm)/serum creatinine (mg/dL). Where height is in cm and serum creatinine is in mg/dL. Children with missing baseline or 2 years GFR were excluded from the analysis. (NCT00006400)
Timeframe: Before initiation of treatment and at 2 years
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Hydroxyurea | 28.65 |
| Placebo | 33.36 |
1 trial available for pentetic acid and Anemia, Sickle Cell
| Article | Year |
|---|---|
Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial.
Topics: Anemia, Sickle Cell; Creatinine; Glomerular Filtration Rate; Humans; Infant; Kidney; Pentetic Acid; | 2010 |
1 other study available for pentetic acid and Anemia, Sickle Cell
| Article | Year |
|---|---|
Cerebral perfusion in children: detection with dynamic contrast-enhanced T2*-weighted MR images.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Blood Flow Velocity; Blood Volume; Cerebrovascular Circulati | 1993 |